Lumira Ventures — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Puzzle Medical develops a heart failure treatment device designed to improve heart and kidney function through 4Fr axillary access, allowing patient ambulation and providing up to seven days of support.
HardwareHealthtechMedical DevicesMontreal
Jade Doucet-Martineau(Co-founder & CEO, Board Director)inFrançois Trudeau(Co-founder & CTO, Board Director)inPhilippe Généreux(Co-founder (Phase 2), Chief Medical Officer & Board Observer)inMaxime Rochon(Co-founder (Phase 2) & VP Clinical, Regulatory and Quality)inYves-Antoine Crête(Co-founder (Phase 2) & VP Technical R&D and Operations)inGabriel Georges(Co-founder & Clinical Advisor)in
Co-investorsBroadview VenturesAjax HealthDesjardins CapitalBoreal VenturesCathexis VenturesFront Row Ventures+3 more
Cardiac Dimensions develops medical technology to treat heart failure caused by functional mitral regurgitation (FMR), aiming to address underlying causes rather than symptoms.
BiotechHealthtechMedical DevicesKirkland, US
Frederick A. Stewart(Executive Officer, Director)Rick Wypych(Executive Officer)in
BoardKurt Wheeler(Director)Nathan Every(Director)Douglas C. Fisher(Director)Gerry Brunk(Director)in
Co-investorsAPERTURE Venture PartnersRedbus VenturesAlly Bridge GroupClaret Capital PartnersJefferiesM.H. Carnegie & Co.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.












